StockData
InflaRx N.V. logo

InflaRx N.V. (IFRX) stock

IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 5/30
$1.18+0.01 (+0.85%)

Close on Nov 16, 2026Market cap $85.31MP/E –Yield –

Earnings

InflaRx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of InflaRx's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2024ended Dec 31, 2024Mar 20, 2025before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

InflaRx has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When InflaRx puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases InflaRx filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?